Cystic fibrosis transmembrane conductance regulator function in patients with chronic pancreatitis

Tobias Schlosser, MD, Daniel Fischer, MD, Sandra Büttner, MD, Valentin Blank, MD, Albrecht Hoffmeister, MD

Abstract
Background: Pathogenesis of chronic pancreatitis (CP) is still not entirely understood with many patients probably having more than 1 underlying etiology. Besides toxic-metabolic factors, genetics contribute to disease development. Mutations in cystic fibrosis transmembrane conductance regulator (CFTR) are shown to increase risk for CP. Activity of CFTR can easily be assessed in vivo by measurement of nasal potential difference (PD).

Methods: We compared in this monocentric study 17 CP patients from the outpatient unit of our university hospital with 30 healthy controls regarding nasal PDs by using a superfusion protocol. Additionally, demographic and lifestyle data of all persons were recorded.

Results: Seventeen patients (12% female, median age 48 years) with CP and 30 healthy volunteers (47% female, 25 years) were included in the study. Patients with CP had a significantly higher proportion of CFTR dysfunction (P = .04). Furthermore, demographics differed between the 2 groups with CP patients being older (P < .001). There were differences in daily alcohol consumption (P = .001) and smoking habits (smokers vs nonsmokers: P = .01, pack years: P = .002).

Conclusions: PD measurement is an easily accessible way to show CFTR dysfunction as an etiological factor of CP. Cigarette smoking might impair CFTR function and therefore be 1 preventable cause of CP evolution.

Abbreviations: CF = cystic fibrosis, CFTR = cystic fibrosis transmembrane conductance regulator, CP = chronic pancreatitis, PD = nasal potential difference, PS = pancreatic sufficiency, PY = pack years, WPI = World Precision Instruments.

Keywords: chronic pancreatitis, cystic fibrosis, nasal potential differences, superfusion

1. Introduction
Cystic fibrosis (CF) is the most common severe autosomal recessive disease among Caucasian population with an incidence of around 1 to 3000 live births.[1] Underlying genetic base are variable mutations within the gene encoding for CF transmembrane conductance regulator (CFTR). These mutations lead to dysfunctional chloride transport, which causes viscous secretions in lungs, pancreas, liver, intestine, and reproductive tract. Most patients develop multisystem disease involving several or all mentioned organs.

CF is associated with different pancreatic diseases, such as exocrine and/or endocrine insufficiency.[5-6] However, acute pancreatitis is a rather infrequent complication of CF (1.24% of all CF patients) and usually occurs in patients with pancreatic sufficiency (PS). Nevertheless, in CF patients with PS an episode of acute pancreatitis is quite frequent (10%-17% of CF patients with PS).[5,6]

Chronic pancreatitis (CP) is a syndrome involving pancreatic inflammation, fibrosis, and loss of function. These conditions lead to a variety of clinical manifestations such as chronic abdominal pain, steatorrhea and maldigestion promoted by exocrine insufficiency, and pancroagogenous diabetes promoted by endocrine insufficiency.[7-9] Annual incidence of CP varies heavily between 1.6 and 23/100.000 persons.[10] Etiologic classification subsets toxic-metabolic, idiopathic, genetic, autoimmune, recurrent acute pancreatitis, and obstructive causes ("TIGAR-O").[11] Within the toxic etiologies, alcohol and nicotine abuse represent by far the most dominant risk factors for CP in western countries.[10]

Diagnosis of CP is based upon clinical conditions, function testing, and typical findings on imaging studies.[9,12] Irreversible tissue damage can be assessed as morphological changes by distinct and complementary modalities. Percutaneous and endoscopic ultrasound reveal characteristic CP patterns as well...
as cross-sectional imaging (CT [computed tomography], MRI [magnetic resonance imaging] / MRCP [magnetic resonance cholangiopancreatography]). Pancreatic calcification as 1 pathognomonic feature may even be visible on plain abdominal radiograph. The Cambridge classification helped to score and unify nomenclature of different imaging techniques and is also part of the M-ANNHEIM scoring system for CP severity. ERCP has lost its diagnostic role to the mentioned noninvasive methods and is reserved for therapeutic use. Histopathological proof as gold standard in CP diagnosis is rarely needed nowadays (eg, to establish diagnosis of autoimmune pancreatitis according to the HISORt criteria).

Therapy of CP consists of pain management, preservation of pancreatic sufficiency or correction of insufficiencies, and management of complications with malignant transformation being one of the severe sequela.

A presumed connection between CF and CP was first described in 1969: 2 siblings with CF were born to a family with 3 paternal relatives suffering from CP. In the 1980s CFTR-mutation was identified as the genetic base of CP.

Due to histopathological (“Cystic fibrosis is basically a diffuse form of chronic pancreatitis.”) and clinical resemblance between CF and CP, Cohn et al and Sharer et al hypothesized and revealed connection between CFTR dysfunction and CP. Indeed, mutations within the CFTR-gene can cause CP with or without manifestations of CF depending on mutation type and zygosity. Thousands of genetic CFTR-variations are known and influence the clinical course of related diseases.

Acute recurrent or CP episodes may precede CF diagnosis. Evolution to CP in homozygous CF patients rarely happens. In a large multinational study only 10 out of 10,071 CF patients had CP. Heterozygous carriers of CFTR-mutations (eg, parents of CF patients) have a 3- to 4-fold risk of developing CP. Genetic analysis of 134 CP patients (71 alcohol related, 60 idiopathic) revealed at least 1 abnormal CFTR-allele in 18 (13,4%) individuals. These subgroup showed significant low nasal potential-difference values without reaching diagnostic threshold for CP. A case-control study presented around twice as much CFTR-mutations (18.6% vs 9.2%; P < .05) in 67 patients suffering from idiopathic CP compared to 60 healthy individuals. A similar study found an over 6-fold ratio of dysfunctional CFTR-genes in patients with undetermined acute, recurrent, or CP (19 of 96 cases, 19%, as compared to 7 of 198 controls, 3.5%; P < .00001).

Given CFTR-mutations as a risk factor for CP, aim of this study was to analyze whether CP is associated with CFTR-dysfunction, measured by nasal potential difference (PD). This method is established as the most sensitive test for CFTR dysfunction in patients suspicious for CP. Furthermore, the influence of smoking regarding CFTR-function in CP was evaluated.

2. Methods

A total of 17 patients with CP had been recruited at the Leipzig University Hospital and examined by nasal PD measurement. Results were compared to the measurements of 30 healthy controls, leading into an unmatched case control study.

Diagnosis of CP were established by an experienced gastroenterologist. Participants had to provide insight of their medical records regarding the exclusion of pancreatic diseases. Missing values were completed by a self-reported questionnaire. Smokers identified themselves without numeric threshold. Alcohol intake was reported on an estimated daily base. Questions referred to the current nicotine and alcohol consumption at the time of the study. Referring to cigarette consumption, pack years (PY) were defined as packs of 20 cigarettes per day multiplied by total years of smoking.

The study was performed in accordance with the guidelines for good clinical practice (E6/R1) and the ethical guidelines of the Helsinki Declaration and was approved by the local ethics committee (University of Leipzig). Informed written consent was obtained from all participants. Neither financial nor nonfinancial benefits were given in return for participation.

PD measurements were conducted according to protocol by Schuler et al: The test person laid his head upon an ophthalmic chin rest while leaning forward to allow the perfusing liquids to exit the nostril. The first in vivo electrode (Ag/AgCl electrode, Fa. World Precision Instruments [WPI], Friedberg, Germany) was placed by the operator under visual guidance into 1 nostril under the inferior turbinate contacting nasal mucosa. This exploring electrode was then secured by tape (Leukosilk S, Fa. BSN Medical, Germany). The second electrode connected a needle (Bendy BD Valu-Set, Fa. Becton Dickinson Industries, NJ) that had been placed subcutaneously in the person’s forearm and served as reference. Basic PD of nasal mucosa was initially measured with a NaCl-perfusion (0.9% sodium chloride, Fa. Baxter, IL). Subsequently followed by measurement under nasal perfusion with amiloride in order to inhibit local sodium channels. Finally, a nonchloride perfusion and perfusion with salbutamol stimulated CFTR function (“superfusion”). Solutions were compounded by the authors especially for this study (Table A1, Supplemental Digital Content, http://links.lww.com/MD/G635). Agar (3%) in Ringer’s solution served as bridging device for the measuring electrodes. PD was graphically presented via voltmeter (Isolated Biological Amplifier, Fa. WPI) and recorded by Data-Trax Data Acquisition Software (Fa. WPI). CFTR dysfunction was defined by missing response to superfusion as indicated by more positive values after salbutamol-perfusion compared to initial PD (Figure A1, Supplemental Digital Content, http://links.lww.com/MD/G635, supplemental content, presenting exemplary curves). Intact nasal mucosa (without, eg, acute rhinitis or recent surgical intervention) was precondition for every measurement.

Statistics and graphics were computed with open access software “R” , version 4.0.4 (The R Foundation for Statistical Computing Vienna, Austria). Chi-squared (Chi^2) testing for binary variables and 2-sided t test for continuous variables checked for inequality between compared groups. Welch modification of t test was used for inhomogeneity of variance, which had been previously tested via Levene test. P-values below 5% served as criterion toward significance.

3. Results

3.1. Patients characteristics

A total of 17 patients (15 men, 2 women) with CP had been prospectively recruited at the Leipzig University Medical Center. Main characteristics are shown in Table 1. The patients had a median age of 48 years (range 31–73 years) at study entry. Fourteen patients (82%) reported a mean alcohol uptake of 60 g per day; 3 patients (18%) claimed no regular alcohol consumption. Eleven CP patients (65%) were self-reported smokers, whereas 6 (35%) didn’t smoke.
Thirty healthy volunteers (16 men, 14 women) served as control group and presented with a higher female proportion compared to CP patients ($P = .04$). The median age was 25 years (range 22–73 years) and the subjects were significantly younger than the CP patients ($P = .001$). Daily alcohol intake ranged from 0 to 20 g with a mean intake of 9 g. Less alcohol consumption was noted ($P < .001$) within the control group. Seven subjects (23%) were smokers and 23 persons (77%) were nonsmokers, showing a higher number of smokers in the CP group ($P = .01$).

### 3.2. Potential differences (PD) and CFTR function

Mean values of PD are provided in Table 2 and shown as boxplots in Figure 1. CP patients presented with a baseline PD of $93.2 \pm 22.3$ mV compared to $83.7 \pm 35.1$ mV in healthy volunteers. Amiloride perfusion resulted in raising PDs toward $70.1 \pm 25.0$ mV in patients with CP and $57.4 \pm 33.1$ mV in healthy volunteers, respectively. Excluding chloride of the perfusions lowered PDs of CP patients to $120 \pm 51.9$ and of control persons to $107 \pm 53.3$ mV. Adding salbutamol lead to a further fall of PD with mean values of $123 \pm 47.2$ mV in CP patients and $128 \pm 56.3$ mV in healthy test persons. Basal potentials as well

### Table 1

| Characteristic | Chronic pancreatitis | Healthy control |
|----------------|----------------------|-----------------|
| **Total**      | 17 100%              | 30 100%         |
| **Etiology**   |                      |                 |
| Alcohol        | 7 41%                | 16 53%          |
| Hereditary     | 1 6%                 | 1 4%            |
| Idiopathic     | 4 24%                | 2 7%            |
| Unknown        | 5 29%                | 5 17%           |
| **Age at diagnosis [yr]** |             |                 |
| Median (range) | 41 (3–64)            |                 |
| **Age at test [years]** |             |                 |
| Median (range) | 48 (31–72)           | 25 (22–73)      |
| **Gender**     |                      |                 |
| Male           | 15 88%               | 16 53%          |
| Female         | 2 12%                | 14 47%          |
| **Alcohol [g/d]** |                |                 |
| Median (range) | 60 (0–200)           | 9 (0–20)        |
| No alcohol     | 3 18%                | 7 23%           |
| **Smoking [pack yr]** |          |                 |
| Median (range) | 11 0–30              | 0 0–10,5        |
| Smoker         | 11 65%               | 7 23%           |
| Nonsmoker      | 6 35%                | 23 77%          |
| **CFTR**       |                      |                 |
| Dysfunction    | 6 35%                | 2 7%            |
| Normal         | 11 65%               | 28 93%          |

| CFTR = cystic fibrosis transmembrane conductance regulator, g/d = gram per day. |
|--------------------------------------|
| Welch modification.                  |
| * $P < .05$.                          |
| ** $P < .01$.                         |
| *** $P < .001$.                        |

### Table 2

| PD [mV] | Chronic pancreatitis | Healthy control | $t$ test |
|---------|-----------------------|-----------------|----------|
|         | Mean (± SD)           | Mean (± SD)     |          |
| Baseline| $-93.2$ (± 22.3)      | $-83.7$ (± 35.1)| 0.26     |
| Amiloride| $-70.1$ (± 25.0)      | $-57.4$ (± 33.1)| 0.18     |
| Chloride-free | $-120$ (± 51.9) | $-107$ (± 53.3) | 0.42     |
| Salbutamol | $-123$ (± 47.2)      | $-128$ (± 56.3) | 0.75     |

| $mV$ = miliVolt, $PD$ = nasal potential differences, $SD$ = standard deviation. |
|--------------------------------------|
| Welch modification.                  |

Figure 1. Grouped boxplots of potential differences under perfusion with NaCl (basal), amiloride, chloride-free solution (0Cl) and salbutamol. Median values are denoted by horizontal bar. Dots represent outliers.
as all perfusion solutions did not differ significantly between CP and control group (exact \( P \)-values ranged from .18–.76, Table 2). Only 2 out of 30 healthy controls (7%) showed decreased response to stimulation, whereas 6 out of 17 (35%) patients with CP presented a reduced salbutamol-response as indicator for CFTR dysfunction (\( P = .04 \), Table 1, Fig. 2, see Figure A2, Supplemental Digital Content, http://links.lww.com/MD/G635, presenting patient characteristics regarding CFTR function, see Table A3, Supplemental Digital Content, http://links.lww.com/MD/G635, presenting PDs regarding CFTR function). Logistic regression shows an odds ratio of 2.03 (standard error 0.89, \( P = .02 \)), that a person with CFTR dysfunction had been diagnosed with CP.

Within the 17 CP patients were 5 smokers, who presented CFTR dysfunction, and 6 smokers with normal CFTR function. The remaining 6 nonsmokers could be separated into 1 CP patient with CFTR dysfunction and 5 with physiological CFTR function. These groups did not show statistical significance regarding chi-squared test (Table 3, \( P = .51 \)).

Comparing the amount of smoking on a daily base showed that CP patients with CFTR dysfunction had a median cigarette consumption of 16 per day, whereas these with normal CFTR function smoked 8 cigarettes per day (\( P = .18 \)). Median amount of PY was significantly associated with CFTR dysfunction (22.5 vs 2.5 PY, \( P = .04 \), Fig. 3, Table 3) within CP patients. This observation disappears when looking at the entire cohort (study group plus healthy volunteers combined, \( P = .25 \), Table 4).

### 4. Discussion

Exact mechanisms of CP development are not entirely understood. One theory is that proteins precipitate and obstruct pancreatic ducts, thus leading to atrophy.\(^4\) Based on that hypothesis, viscous ductal fluid due to decreased CFTR function might be 1 key point in pathogenesis of CP.\(^28\)

Malfunctioning CFTR had been observed in distinct etiologies such as idiopathic, alcoholic and autoimmune CP.\(^29\) Cigarette smoke does suppress CFTR function in vitro as well as in vivo, observed by nasal PD measurement of smokers without genetic alterations.\(^30\) Our data support that idea as we show significant decrease of CFTR activity in nasal PD measurements within the

---

**Table 3**

| Smoking and CFTR function in CP patients. | CFTR dysfunction | CFTR normal | \( \chi^2 \) | \( t \) test |
|------------------------------------------|------------------|-------------|-------------|-----------|
| Median of daily cigarette consumption    | 16               | 8           | 0.180       |           |
| Median of cigarette pack years           | 22.5             | 2.5         | 0.042\(^*\) |           |
| Smoker                                   | 5                | 6           | 0.51        |           |
| Nonsmoker                                | 1                | 5           |             |           |

\( \chi^2 = \text{cystic fibrosis transmembrane conductance regulator, CP} = \text{chronic pancreatitis.} \)

\( * P < .05. \)

---

**Table 4**

| Smoking and CFTR function in CP and non-CP patients. | CFTR dysfunction | CFTR normal | \( \chi^2 \) |
|------------------------------------------------------|------------------|-------------|-------------|
| Smoker                                               | 5                | 13          | 0.25        |
| Nonsmoker                                            | 3                | 26          |             |

\( \chi^2 = \text{cystic fibrosis transmembrane conductance regulator, CP} = \text{chronic pancreatitis.} \)
CP cohort (Table 1) but not within the entire cohort (Table 4). This could represent 1 hint, that CP patients might present a special pathogenic susceptibility towards tobacco use. Furthermore, there seems to be a dose depending effect as the consumed PY show effect on CFTR function, but not the daily number of cigarettes (Table 3). These 2 observations combined might support our idea that cigarette smoke contributes to pathogenesis of CP via interfering CFTR activity.

Exact mechanism of decreased CFTR activity in smokers is yet not established. Internalization of the channel due to cigarette consumption might be 1 explanation that was derived from in vitro experiments. Direct CFTR inhibition by reactive smoke intermediates might as well contribute. Furthermore, smoke leads to degradation of CFTR and might also contribute to associated diseases. Besides smoking cessation, there might also be a pharmacological approach to re-establish CFTR function with therapeutic intention.

Therefore, we hypothesize that cigarette consumption as risk factor for CP development might be mediated by smoking-induced CFTR dysfunction.

Our study results have some limitations that must be taken into consideration: Change of smoking habits or in alcohol consumption over time were not recorded. Especially when diagnosed with CP you might expect cessation or reduction of these well-known risk factors according to medical advice. Besides, the self-report of these habits might tend to be biased by desirability in order to dissimulate unhealthy behavior and simulate medical compliance. Moreover, self-assessment of data is lacking objectiveness and tend to include systemic bias. Another limitation of the study is the heterogeneity of the investigated groups. This is mainly a result of a selection bias within the unmatched case control design of our study that is lacking a stratified randomly sampled control group. Nevertheless, the differences between the groups seem quite reasonable: Although there is a well-known “gender gap” in CF as role model of CFTR associated disease, genetics lead to an equally balanced influence and is mirrored in higher male ratio when epidemiology associates over time were not recorded. Especially when diagnosed with CP you might expect cessation or reduction of these well-known risk factors according to medical advice. Moreover, the self-report of these habits might tend to be biased by desirability in order to dissimulate unhealthy behavior and simulate medical compliance. Moreover, self-assessment of data is lacking objectiveness and tend to include systemic bias.

Our study results have some limitations that must be taken into consideration: Change of smoking habits or in alcohol consumption over time were not recorded. Especially when diagnosed with CP you might expect cessation or reduction of these well-known risk factors according to medical advice. Moreover, the self-report of these habits might tend to be biased by desirability in order to dissimulate unhealthy behavior and simulate medical compliance.

## Acknowledgments
We acknowledge support from Leipzig University for Open Access Publishing.

## Author contributions

**Conceptualization:** Tobias Schlosser, Daniel Fischer, Sandra Büttner, Albrecht Hoffmeister.

**Data curation:** Tobias Schlosser, Daniel Fischer, Sandra Büttner.

**Formal analysis:** Tobias Schlosser.

**Investigation:** Tobias Schlosser, Daniel Fischer, Sandra Büttner, Valentin Blank, Albrecht Hoffmeister.

**Methodology:** Tobias Schlosser, Valentin Blank, Albrecht Hoffmeister.

**Project administration:** Albrecht Hoffmeister.

**Resources:** Tobias Schlosser, Albrecht Hoffmeister.

**Software:** Tobias Schlosser.

**Supervision:** Albrecht Hoffmeister.

**Visualization:** Tobias Schlosser.

**Writing – original draft:** Tobias Schlosser.

**Writing – review & editing:** Valentin Blank, Albrecht Hoffmeister.

## References

1. Hamosh A, FitzSimmons SC, Macek M, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 1998;132:2255-9.
2. Bronstein MN, Sokol RJ, Abman SH, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992;120:533–40.
3. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros 2013;12:318–31.
4. Singh VK, Yadav D, Garg PK. Diagnosis and management of chronic pancreatitis: a review. JAMA 2019;322:2422–34.
5. Boeck K de, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics 2005;115:e463–9.
6. Durno C, Corey M, Zienielski J, Tullis E, Tsui L-C, Durie P. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 2002;123:1857–64.
7. Whitcomb DC, Frulloni L, Garg P, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. Pancreatology 2016;16:218–24.
8. Majumder S, Chari ST. Chronic pancreatitis. Lancet 2016;387:1957–66.
9. Hoffmeister A, Mayerle J, Børglmer C, et al. English language version of the S3-consensus guidelines on chronic pancreatitis: definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Z Gastroenterol 2015;53:1447–95.
10. Dufour MC, Adamson MD. The epidemiology of alcohol-induced pancreatitis. Pancreas 2003;27:286–90.
11. Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001;120:682–707.
12. Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG clinical guideline: chronic pancreatitis. Am J Gastroenterol 2020;115:322–39.
13. Sarner M, Cotton PB. Classification of pancreatitis. Gut 1984;25:756–9.
14. Schneider A, Löhr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol 2007;42:101–19.
15. Chari ST, Takayasu N, Levy MJ, et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009;7:1097–103.
16. Paris J, Farriau JP, Gérard A, Merville P. Etude des pancréatopathies observées dans les trois générations d’une même famille. Lille Med 1969;14:588–94.
[17] Rommens J, Iannuzzi M, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-65.

[18] Longnecker DS. Pathology and pathogenesis of diseases of the pancreas. Am J Pathol 1982;107:99-121.

[19] Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic chronic pancreatitis. N Engl J Med 1998;339:653-8.

[20] Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998;339:645-52.

[21] Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2000;67:471-85.

[22] Hasen A, Moscoso DI, Kastrinos F. The role of genetics in pancreatitis. Gastrointest Endosc Clin N Am 2018;28:587-603.

[23] Baldwin C, Zerofsky M, Sathe M, Troendle DM, Perito ER. Acute recurrent and chronic pancreatitis as initial manifestations of cystic fibrosis and cystic fibrosis transmembrane conductance regulator-related disorders. Pancreas 2019;48:888-93.

[24] Weiss FU, Simon P, Bogdanova N, et al. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut 2005;54:1456-60.

[25] Choudari CP, Imperiale TF, Sherman S, Fogel E, Lehman GA. Risk of pancreatitis with mutation of the cystic fibrosis gene. Am J Gastroenterol 2004;99:1358-63.

[26] Schüler D, Sermet-Gaudelus I, Wilschanski M, et al. Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 2004;3(Suppl 2):151-5.

[27] Andres Houseman E. Using R for introductory statistics. John Verzani, 2004.

[28] Hegyi P, Wilschanski M, Muallem S, et al. CFTR: a new horizon in the pathomechanism and treatment of pancreatitis. Rev Physiol Biochem Pharmacol 2016;170:37-66.

[29] Ko SBH, Mizuno N, Yatabe Y, et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology 2010;138:1988-96.

[30] Marklew AJ, Patel W, Moore PJ, et al. Cigarette smoke exposure induces retrograde trafficking of CFTR to the endoplasmic reticulum. Sci Rep 2019;9:13655.

[31] Rab A, Rowe SM, Raju SV, Bebok Z, Matalon S, Collawn JF. Cigarette smoke and CFTR: implications in the pathogenesis of COPD. Am J Physiol Lung Cell Mol Physiol 2013;305:L530-41.

[32] Xu X, Balsiger R, Tyrrell J, Boyaka PN, Tarran R, Cornet-Boyaka E. Cigarette smoke exposure reveals a novel role for the MEK/ERK1/2 MAPK pathway in regulation of CFTR. Biochim Biophys Acta 2013;1830:1224-32.

[33] Raju SV, Rasmussen L, Sloane PA, Tang LP, Libby EF, Rowe SM. Rolflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice. Respir Res 2017;18:173.

[34] Courville CA, Raju SV, Liu B, Accurso FJ, Dransfield MT, Rowe SM. Recovery of acquired cystic fibrosis transmembrane conductance regulator dysfunction after smoking cessation. Am J Respir Crit Care Med 2015;192:1221-4.

[35] Dutta RK, Chinnapaiyan S, Rasmussen L, Raju SV, Unwalla HJ. A neutralizing aptamer to TGFBR2 and miR-145 antagonism rescue cigarette smoke- and TGF-β-mediated CFTR expression. Mol Ther 2019;27:442-55.

[36] Furnham A. Response bias, social desirability and dissimulation. Personal Individ Differ 1986;7:385-400.

[37] Tempelaar D, Riettees B, Nguyen Q. Subjective data, objective data and the role of bias in predictive modelling: lessons from a dispositional learning analytics application. PLoS One 2020;15:e0233977.

[38] Lam GY, Goodwin J, Wilcox PG, Quon BS. Sex disparities in cystic fibrosis: review on the effect of female sex hormones on lung pathophysiology and outcomes. ERJ Open Res 2021;7: doi: 10.1183/23120341.00475-2020.

[39] Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 2013;144:1252-61.

[40] Wilcox CM, Sandhu BS, Singh V, et al. Racial differences in the clinical profile, causes, and outcome of chronic pancreatitis. Am J Gastroenterol 2016;111:1488-96.

[41] Dani R, Mott CB, Guarita DR, Nogueira CE. Epidemiology and etiology of chronic pancreatitis in Brazil: a tale of two cities. Pancreas 1990;5:474-8.

[42] WHO Report on the Global Tobacco Epidemic, 2019: Offer Help to Quit Tobacco Use. Geneva, Switzerland: World Health Organization; 2019.

[43] Global Status Report on Alcohol and Health 2018. 2018;World Health Organization.

[44] Yadav D, Hawes RH, Brand RE, et al. Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med 2009;169:1035-45.